Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Myriad Genetics ( (MYGN) ) just unveiled an announcement.
On July 31, 2025, Myriad Genetics entered into a $200 million credit agreement with OrbiMed Royalty & Credit Opportunities IV, LP, which includes a $125 million initial loan and an option for an additional $75 million until June 30, 2027. This credit facility, secured by Myriad’s assets, will support the company’s working capital needs and growth strategy, replacing its previous ABL facility.
The most recent analyst rating on (MYGN) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page.
Spark’s Take on MYGN Stock
According to Spark, TipRanks’ AI Analyst, MYGN is a Neutral.
Myriad Genetics’ overall score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis supports a bearish outlook, further pressuring the stock. Valuation remains a concern with a negative P/E ratio. Despite some positive aspects from the earnings call, the revised guidance and operational challenges weigh heavily on the stock’s prospects.
To see Spark’s full report on MYGN stock, click here.
More about Myriad Genetics
Myriad Genetics is a leading company in the molecular diagnostic testing and precision medicine industry. The company develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, aiming to improve patient care and reduce healthcare costs.
Average Trading Volume: 2,162,823
Technical Sentiment Signal: Sell
Current Market Cap: $377.9M
Find detailed analytics on MYGN stock on TipRanks’ Stock Analysis page.